Mueller V, Wardley A, Paplomata E, et al. - This study was undertaken to investigate the effect of tucatinib on health-related quality of life (HR-QoL) in HER2CLIMB. Individuals were assigned randomly in a 2:1 ratio to tucatinib or placebo combined with trastuzumab and capecitabine. In this study, 331 (91%) completed ≥1 assessment among 364 patients eligible for HR-QoL assessment. It was shown that EQ-VAS scores were similar for both arms at baseline and maintained throughout treatment. This study’s findings illustrate that HR-QoL was preserved for patients with HER2+ metastatic breast cancer who were treated with tucatinib added to trastuzumab and capecitabine and maintained longer with tucatinib therapy than without it among those with brain metastases.